Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03559088
Other study ID # 17129
Secondary ID I5Q-MC-CGBA
Status Completed
Phase N/A
First received
Last updated
Start date June 11, 2018
Est. completion date April 26, 2019

Study information

Verified date July 2020
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether using a smart phone application to foster communication between study participants and their doctor will impact care. Participants must have a history of migraine or have recently been prescribed a common medicine to treat migraine. The study will last about one year for each participant.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date April 26, 2019
Est. primary completion date April 26, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Have a diagnosis of migraine (ICD10: G43.*) since October 2015 OR a record of being prescribed a triptan prior to study

- Have not been prescribed a preventive migraine medication within the past twelve months

- Have not visited a neurologist in the past year

- Have an upcoming visit with their Atrium Health primary care provider

Exclusion Criteria:

- Do not own an iOS or Android smart phone with a data plan or are unwilling to install the app on their phone

- Are currently participating in a clinical trial involving an investigational drug

- Have previously used the app used in this study

- Are pregnant at the time of study entry

- Are not able to provide informed consent

- Cannot speak and read English fluently

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Migraine App
Smart phone app used to report migraine burden to the EHR.

Locations

Country Name City State
United States Carmel Family Physicians Charlotte North Carolina
United States Charlotte Internal Medicine Charlotte North Carolina
United States Charlotte Medical Clinic Charlotte North Carolina
United States Charlotte Medical Clinic-South Park Charlotte North Carolina
United States Mecklenburg Medical Group - Ballantyne Charlotte North Carolina
United States Randolph Internal Medicine Charlotte North Carolina
United States South Charlotte Primary Care Charlotte North Carolina
United States Shiland Family Fort Mill Fort Mill South Carolina
United States Shiland Family Practice Fort Mill South Carolina
United States Table Rock Family Medicine Glen Alpine North Carolina
United States Mecklenburg Medical Group - Northcross Huntersville North Carolina
United States North Charlotte Medical Specialists - Huntersville Huntersville North Carolina
United States Lincoln Family Practice Lincolnton North Carolina
United States Mecklenburg Medical Group - Matthews Matthews North Carolina
United States Union Family Practice Monroe North Carolina
United States Troy Medical Services Troy North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Eli Lilly and Company Atrium Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Receiving a Preventive Migraine Prescription Number of Participants Receiving a Preventive Migraine Prescription Next primary care appointment following use of app (estimated as 5 weeks)
Secondary Number of Months of App Use Number of Months of App Use Baseline through one year
Secondary Number of Participants Receiving Acute and Preventive Migraine Treatments, Opioids, Barbiturates Number of Participants Receiving Acute and Preventive Migraine Treatments, Opioids, Barbiturates Baseline through one year
Secondary Number of Acute Care Visits Number of Acute Care Visits Baseline through one year
Secondary Number of Primary Care Visits Number of Primary Care Visits Baseline through one year
Secondary Number of Emergency Room Visits Number of Emergency Room Visits Baseline through one year
Secondary Number of Urgent Care Visits Number of Urgent Care Visits Baseline through one year
Secondary Number of Referrals to a Neurologist Number of Referrals to a Neurologist Baseline through one year
Secondary Number of New Diagnoses of Migraine or Chronic Migraine Diagnoses made by International Classification of Diseases 10th revision (ICD10) coding system Baseline through one year
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A
Completed NCT01741246 - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging N/A